Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line

Gynecologic Oncology

Volumn 97, Issue 1, 2005, Pages 26-34

  Lee, Sooyong ^a,b   Choi, Eui Ju ^b   Jin, Changbae ^a   Kim, Dong Hyun ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

Author keywords

Apoptosis; Bax translocalization; Cisplatin resistance; Cytochrome c; OVCAR 3 cells; PI3K Akt; PIK3CA; PTEN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN KINASE B; PROTEIN P110; SMALL INTERFERING RNA; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CLONE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE FUNCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE; OVARY CANCER; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 15544369937     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.11.051     Document Type: Article

References (33)

1. B. Rosenberg Platinum complexes for the treatment of cancer Lippert B. Cisplatin Chemistry and Biochemistry of a Leading Anticancer Drug 1999 Wiley-VCH Basel, Switzerland 3 37
2. P.A. Andrews, S. Velury, S.C. Mann, and S.B. Howell cis- Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells Cancer Res. 48 1988 68 73
3. A.K. Godwin, A. Meister, P.J. O'Dwyer, C.S. Huang, T.C. Hamilton, and M.E. Anderson High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc. Natl. Acad. Sci. U. S. A. 89 1992 3070 3074
4. S.L. Kelley, A. Basu, B.A. Teicher, M.P. Hacker, D.H. Hamer, and J.S. Lazo Overexpression of metallothionein confers resistance to anticancer drugs Science 241 1998 1813 1815
5. R.J. Parker, A. Eastman, F. Bostick-Bruton, and E. Reed Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation J. Clin. Invest. 87 1991 772 777
6. R.P. Perez Cellular and molecular determinants of cisplatin resistance Eur. J. Cancer 34 1998 1535 1542
7. K.M. Henkels, and J.J. Turchi Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines Cancer Res. 59 1999 3077 3083
8. J. Li, Q. Feng, J.M. Kim, D. Schneiderman, P. Liston, and M. Li Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins Endocrinology 142 2001 370 380
9. J.R. Liu, A.W. Opipari, L. Tan, Y. Jiang, Y. Zhang, and H. Tang Dysfunctional apoptosomal activation in ovarian cancer: implications for chemoresistance Cancer Res. 62 2002 924 931
10. J. Hawakawa, M. Ohmichi, H. Kurachi, Y. Kanda, K. Hisamota, and Y. Nishio Inhibition of Bad phosphorylation either at serine 112 via extracellular signal regulated protein kinase cascade or at ser 136 via Akt cascades sensitizes human ovarian cancer cells to cisplatin Cancer Res. 60 2000 5988 5994
11. S.R. Datta, A. Brunet, and M.E. Greenberg Cellular survival: a play in three Akts Genes Dev. 13 1999 2905 2907
12. S.G. Kennedy, A.G. Wagner, S.D. Conzen, J. Jordan, A. Bellacosa, and P.N. Tsichlis The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal Genes Dev. 11 1997 701 713
13. L. Shayesteh, Y. Lu, W.L. Ku, R. Baldocchi, T. Godfrey, and C. Collins PIK3CA is implicated as an oncogene in ovarian cancer Nat. Genet. 21 1999 99 102
14. V. Stambolic, A. Suzuki, J.L. de la Pompa, G.M. Brothers, C. Mirtsos, and T. Sasaki Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 95 1998 29 39
15. K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, and C. Eng Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not in associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am. J. Pathol. 158 2001 2097 2105
16. G.W. Makin, B.M. Corfe, G.J. Griffiths, A. Thistlethwaite, J.A. Hickman, and C. Dive Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimmers/complexes occur regardless of cell fate EMBO J. 15 2001 6306 6315
17. T.F. Gajewski, and C.B. Thompson Apoptosis meets signal transduction: elimination of a bad influence Cell 87 1996 589 592
18. J. Zha, H. Harada, E. Yang, J. Jockel, and S.J. Korsmeyer Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not Bcl-XL Cell 87 1996 619 628
19. J. Won, D.Y. Kim, M. La, D. Kim, G.G. Meadows, and C.O. Joe Cleavages of 14-3-3 protein by caspase-3 facilitates Bad interaction with Bcl-x(L) during apoptosis J. Biol. Chem. 278 2003 19347 19351
20. D.M. Finucane, E. Bossy-Wetzel, N.J. Waterhouse, T.G. Cotter, and D.R. Green Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-XL J. Biol. Chem. 274 1999 2225 2233
21. E. Asselin, G.B. Mills, and B.K. Tsang XIAP regulates Akt activity and caspase-3-dependent cleavages during cisplatin-induced apoptosis in human ovarian epithelia cancer cells Cancer Res. 61 2001 1862 1868
22. S.G. Kennedy, E.S. Kandel, T.K. Cross, and N. Hay Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria Mol. Cell. Biol. 19 1999 5800 5819
23. H. Zhou, X.M. Li, J. Meinkoth, and R.N. Pittman Akt regulates cell survival and apoptosis at a postmitochondrial level J. Cell Biol. 151 2000 484 494
24. F. Tsuruta, N. Masuyanam, and Y. Gotoh The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria J. Biol. Chem. 277 2000 14040 14047
25. M.P. Myers, I. Pass, I.H. Batty, J. Van Der Kaay, J.P. Stolarov, and B.A. Hemmings The lipid phosphatase activity of PTEN is critical for its tumor suppressor function Proc. Natl. Acad. Sci. U. S. A. 95 1998 13513 13518
26. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1 dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J. Biol. Chem. 273 1998 13375 13378
27. M.M. Georgescu, K.H. Kirsch, T. Akagi, T. Shishido, and H. Hanafusa The tumor-suppressor activity of PTEN is regulated by its carboxy-terminal region Proc. Natl. Acad. Sci. U. S. A. 96 1999 10182 10187
28. F. Vazquez, S. Ramaswamy, N. Nakamura, and W. Sellers Phosphorylation of the PTEN tail regulates protein stability and function Mol. Cell. Biol. 20 2000 5010 5018
29. F. Vazquez, S.R. Grossman, Y. Takahashi, M.V. Rokas, N. Nakamura, and W.R. Sellers Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex J. Biol. Chem. 276 2001 48627 48630
30. K. Obata, S.J. Morland, R.H. Watson, A. Hitchcock, G. Chenevix-Trench, and E.J. Thomas Frequent PTEN/MMAC mutations in endometroid but not serous or mucinous epithelial ovarian tumors Cancer Res. 58 1998 2095 2097
31. G.L. Maxwell, J.I. Risinger, B. Tong, H. Shaw, J.C. Barrett, and A. Berchuck Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers Gynecol. Oncol. 70 1998 13 16
32. J. Woenckhaus, K. Stegar, E. Werner, I. Fenic, U. Gamerdinger, and T. Dreyer Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma J. Pathol. 198 2002 335 342
33. D.S. Byun, K. Cho, B.K. Ryu, M.G. Lee, J.I. Park, and K.S. Chae Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinomas Int. J. Cancer 104 2003 318 327